Sera Prognostics, Inc.

Sera Prognostics, Inc.

SERA·NASDAQ

$2.25

+9.5%
HealthcareMedical - Diagnostics & Research

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

At a Glance

Live Snapshot
Market Cap$85.74M
EPS-0.6700
P/E Ratio-3.35
Earnings Date08/05/2026

sera

Other Current Assets

Last Annual Value

1.56M

3-Year CAGR

6%

5-Year CAGR

%

10-Year CAGR

%

Sera Prognostics, Inc.

Sera Prognostics, Inc. Competitors Analysis of Other Current Assets

SERA · NASDAQ
CompanyOther Current Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
1.56M
25.1%N/AN/A 
2.15M
54.9%37.3%N/A
1.35M
-21.2%N/A5.7%
2.36M
13.9%N/AN/A
DCGO logo
DocGo Inc.
NASDAQ:DCGO
3.70M
-40.4%N/AN/A
20.81M
2650.7%50.7%56.1%
2.15M
40.1%-6.1%22.4%
1.59M
188.6%58.4%14.8%
1.51M
-12.7%N/A9.6%
-35.02B
N/AN/AN/A
1.00M
84.5%49.3%-1.9%
Sera Prognostics, Inc.

Sera Prognostics, Inc. Fair Value Envelope

SERA · NASDAQ

Our analysis suggests that SERA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.245, this represents a potential HIDDEN relative to our calculated worth for Sera Prognostics, Inc..

Intrinsic Value
Current Price: $2.245